Showing 731-740 of 987 results for "".
- Revision Skincare Unveils New "The Science Is Black and White" Brand Campaignhttps://modernaesthetics.com/news/revision-skincare-unveils-new-the-science-is-black-and-white-brand-campaign/2473507/Revision Skincare is rolling out its new brand campaign: "The Science Is Black and White." The campaign, which emphasizes that there are no gray areas when it comes to results, speaks to both consumers and skincare providers. Revision Skincare will be cel
- Hair Relaxers Linked to Uterine Cancer in Black Womenhttps://modernaesthetics.com/news/hair-relaxers-linked-to-uterine-cancer-in-black-women/2473506/Long-term use of chemical hair relaxers by postmenopausal Black women may increase risk of uterine cancer, according to a new study by researchers at Boston University’s Black Women’s Health Study (BWHS). These products contain potentially harmful ingredients, including chem
- Study: Belotero Balance (+) Restores Volume to Under-eye Hollowshttps://modernaesthetics.com/news/study-belotero-balance-restores-volume-to-under-eye-hollows/2473429/Belotero Balance® (+) corrects volume loss in the infraorbital hollow area, according to new data from Merz Aesthetics. Merz Aesthetics will submit these data as part of a supplemental Premarket Approval Application (sPMA) with the U.S. Food and Drug Administration (FDA) this
- Updated: Cutera CEO, Executive Chairman Axedhttps://modernaesthetics.com/news/cutera-ceo-top-investor-call-for-removal-of-board-members/2473390/Cutera Inc has fired CEO David Mowry and Executive Chairman Daniel Plants for alleged violations of their employment contracts. Sheila Hopkins has been appointed as interim CEO and the search for a permanent replacement is underway. Plants and Mowry called for a Spec
- Cutera Unveils Updated truBody Brandhttps://modernaesthetics.com/news/cutera-unveils-updated-trubody-brand/2473378/Cutera has launched an updated truBody brand that pairs two technologies designed to create a customized, convenient, and complete approach to fat reduction and muscle toning with 15-minute treatment options, according to a company news release. The new truBody brand elevates both pract
- CoolHealth Rolls Out TargetCool for Post-Procedure Pain Controlhttps://modernaesthetics.com/news/coolhealth-rolls-out-targetcool-for-post-procedure-pain-controlmo/2473359/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and secon
- The Aesthetic Society and ASERF Unveil Findings From The Biospecimen Study On Breast Implant Illnesshttps://modernaesthetics.com/news/the-aesthetic-society-the-aesthetic-surgery-education-and-research-foundation-unveil-findings-from-the-biospecimen-study-on-breast-implant-illness/2473325/
- Few Patients Undergo Recommended MRI Screening After Silicone Implant Breast Surgeryhttps://modernaesthetics.com/news/few-patients-undergo-recommended-mri-screening-after-silicone-implant-breast-surgery/2473272/Only six percent of women with silicone breast implants followed the previous FDA recommendation for regular magnetic resonance imaging (MRI) screening, suggests a study in Plastic and Reconstructive Surgery®, the o
- Study: Skin of Color Patients Are Under-represented in Cosmetic Clinical Trialshttps://modernaesthetics.com/news/study-skin-of-color-patients-are-under-represented-in-cosmetic-clinical-trials/2473221/There’s a lack of ethnic/racial diversity in industry-sponsored aesthetic trials, according to new research in the April 2022 issue of Lasers in Surgery and Medicine. Researchers, led by Lisa Akintilo MD, MPH a current PGY-4 dermatology resident at New York
- Jeune Aesthetics Shares Positive Clinical Phase 1 Data for Investigational Gene-based Treatment to Address the Underlying Biology of Aging Skinhttps://modernaesthetics.com/news/jeune-aesthetics-shares-positive-clinical-phase-1-data-for-investigational-gene-based-treatment-to-address-the-underlying-biology-of-aging-skin/2473210/Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal Biotech, Inc. shared positive proof-of-concept efficacy data from Cohort 2 of its PEARL-1 study of KB301, Jeune Aesthetics’ lead candidate for the treatment of aesthetic skin conditions. “We are pleased to see